Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age

Kondalsamy-Chennakesavan, Srinivas and Hackethal, Andreas and Bowtell, David and Obermair, Andreas (2013) Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. Gynecologic Oncology, 129 (3). pp. 467-471. ISSN 0090-8258

Abstract

Objective: Evaluating the presence of possible malignant disease in women with ovarian masses relies on medical imaging and serum marker findings. This study considers the role of serum Human Epididymal Protein 4 (HE4) antigen in combination with other serum markers to more effectively estimate the risk of malignancy in patients with isolated pelvic masses.
Methods: We used prospectively collected biospecimens held by the Australian Ovarian Cancer Study (AOCS). Serum samples of patients with FIGO stage 1 epithelial ovarian cancer or with a benign condition were analysed for levels of circulating HE4 antigen, CA 125, and CEA, and test results were used to predict the presence of malignancy and to differentiate benign from malignant pelvic masses. Results: HE4 levels were significantly elevated amongst postmenopausal women and amongst patients with malignancy compared to premenopausal women and those with benign disease (p < 0.001 for both). The combination of CA125 and age, achieved an area under the ROC curve of 0.677 (95% CI: 0.584 to 0.770, p = 0.778), whilst HE4 + CA125 + CEA in combination with patient's age showed significantly higher AUC of 0.797 (95% CI: 0.721 to 0.874, p = 0.0052). By adjusting the ROMA cut-off values the percentage of correctly classified premenopausal patients into low and high risk groups increased from 36.99% to 69.86%. Conclusions: In patients with isolated pelvic masses, the combination of HE4, CA 125 and age with or without CEA provides higher diagnostic value compared to CA125 and age alone. It may therefore be considered for continuous evaluation in patients with adnexal masses.


Statistics for USQ ePrint 23724
Statistics for this ePrint Item
Item Type: Article (Commonwealth Reporting Category C)
Refereed: Yes
Item Status: Live Archive
Additional Information: © 2013 Elsevier Inc. Published version deposited in accordance with the copyright policy of the publisher.
Faculty / Department / School: Historic - Faculty of Sciences - No Department
Date Deposited: 11 Jul 2013 04:17
Last Modified: 14 Jul 2014 05:33
Uncontrolled Keywords: adnexal mass; CA-125; CEA; HE4; ovarian cancer
Fields of Research : 11 Medical and Health Sciences > 1112 Oncology and Carcinogenesis > 111201 Cancer Cell Biology
10 Technology > 1004 Medical Biotechnology > 100402 Medical Biotechnology Diagnostics (incl. Biosensors)
11 Medical and Health Sciences > 1112 Oncology and Carcinogenesis > 111202 Cancer Diagnosis
Socio-Economic Objective: C Society > 92 Health > 9202 Health and Support Services > 920203 Diagnostic Methods
Identification Number or DOI: 10.1016/j.ygyno.2013.03.001
URI: http://eprints.usq.edu.au/id/eprint/23724

Actions (login required)

View Item Archive Repository Staff Only